Trials / Conditions / Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
6 registered clinical trials studyying Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Active Not Recruiting | Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy NCT04665765 | City of Hope Medical Center | Phase 2 |
| Terminated | CD19-Specific T Cells Post AlloSCT NCT03579888 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy NCT04409314 | University of California, San Francisco | — |
| Terminated | Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients Wit NCT04205838 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphom NCT04007029 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. NCT03150329 | City of Hope Medical Center | Phase 1 |